Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MRE11 | P49959 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | CPA1 | P15085 | 2/20 | 0.35 |
| ▸ | CPB1 | P15086 | 1/20 | 0.35 |
| ▸ | CPA3 | P15088 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 2/20 | 0.34 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.34 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488443 | 1.00 | KMT2A (0.38) | KMT2AMEN1MRE11L3MBTL1ALDH1A1 | |
| SCHEMBL4607364 | 0.90 | KMT2A (0.40) | KMT2AMEN1ALDH1A1CPA1CPB1 | |
| SCHEMBL3520494 | 0.86 | CPB2 (0.49) | KMT2AMEN1MRE11L3MBTL1CPA1 | |
| SCHEMBL3520496 | 0.86 | CPB2 (0.49) | KMT2AMEN1MRE11L3MBTL1CPA1 | |
| SCHEMBL4501949 | 0.83 | KMT2A (0.36) | KMT2AMEN1L3MBTL1ALDH1A1FFAR1 | |
| SCHEMBL4501945 | 0.83 | KMT2A (0.36) | KMT2AMEN1L3MBTL1ALDH1A1FFAR1 | |
| SCHEMBL5107901 | 0.80 | ALDH1A1 (0.41) | KMT2AMEN1MRE11ALDH1A1 | |
| SCHEMBL4490748 | 0.80 | ALDH1A1 (0.41) | KMT2AMEN1MRE11ALDH1A1 | |
| SCHEMBL14032563 | 0.80 | ALDH1A1 (0.41) | KMT2AMEN1MRE11ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5107894 | 0.78 | ALDH1A1 (0.43) | KMT2AMEN1MRE11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528129-B2 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-05 | — | — | US | disclosed |
| US-20060252931-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252931-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | KMT2A 4813/4885MEN1 678/4885MRE11 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.